The following is a summary of the Nissan Motor Co., Ltd. (NSANY) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Nissan reported net revenue of around ¥3 trillion, with operating profit at ¥1 billion, and net income at ¥28.6 billion.

• Total global retail sales remained flat with 787,000 units sold.

• Capital expenditure accelerated to ¥100.8 billion and R&D investment was ¥147.9 billion to support future strategic initiatives.

• Automotive business net revenue slightly increased to ¥2.68 trillion, however, there was an operating loss of ¥74 billion and negative auto free cash flow of ¥302.8 billion.

Business Progress:

• In Japan, despite an overall decline, success was notable in the Kei car segment with improved sales of refreshed DAYZ and ROOX models, along with a strengthening in order intake.

• In North America, despite a decrease in sales due to aging products and delayed model year changeovers, Nissan retained its top sales position in Mexico.

• In Europe, strong demand for e-POWER variants pushed retail sales up and received positive market feedback.

• New models like Ariya NISMO, Qashqai in Europe, and Pathfinder in China have been launched.

Opportunities:

• Nissan's operational adjustments and model refreshments, like the new Qashqai e-POWER, are anticipated to drive future sales.

• Investments in R&D and CapEx underline Nissan's commitment to innovation and maintaining a competitive edge, especially with the continued shift toward electrification and new energy vehicles.

Risks:

• Faced challenges in the U.S. market with a decline in sales volumes and increased promotional incentives, particularly due to delayed model changeovers affecting main models like Rogue and Sentra.

• Economic pressures and intense market competition, especially in China, negatively impacted sales and required significant inventory adjustments.

More details: Nissan Motor (ADR) IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.